The FDA announced Friday that it had approved the first at-home test for sexually transmitted infections, opening the pathway ...
The Visby Medical Women's Sexual Health Test received marketing authorization to diagnose chlamydia, gonorrhea, and trichomoniasis in women ...
The FDA has approved fitusiran, now named Qfitlia, for routine prophylaxis in patients aged 12 and older with hemophilia A or ...
Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase ...
The U.S. Food and Drug Administration (FDA) has announced the approval of Qfitlia (fitusiran), a treatment designed to ...
The U.S. Food and Drug Administration on Friday approved Sanofi SA’s (NASDAQ:SNY) Qfitlia (fitusiran), the first antithrombin ...
Gvoke VialDx is expected to be available in the third quarter of 2025. The Food and Drug Administration (FDA) has approved Gvoke VialDx â„¢ (glucagon) for intravenous use as a diagnostic aid ...
Investing.com -- The US Food and Drug Administration (FDA) has approved Sanofi (NASDAQ: SNY )’s treatment for hemophilia, Qfitlia (fitusiran), which can be administered as infrequently as once every ...
The US Food and Drug Administration (FDA) has granted marketing authorization for the first at-home test to diagnose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results